Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

  • STATUS
    Recruiting
  • days left to enroll
    50
  • participants needed
    12
  • sponsor
    Ruijin Hospital
Updated on 22 September 2021

Summary

The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.

Description

This phase I study is being conducted to establish safety, pharmacokinetics, and preliminary efficacy of intravenous (IV) mRNA electroporated fully-humanized anti-MESO re-directed autologous T cell administration in patients with chemotherapy-refractory metastatic solid tumors.

The study will adopt the "3+3" dose escalation design exploring two doses of 1109 and 3109. The administration is planned to infuse 3 times a week for 2 consecutive weeks.

The subjects will receive a total dose of 1x109 RNA transduced anti-MESO CAR-T cells in the first week, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. If there is no obvious dose-limiting toxicity (DLT) after the first week of infusion, three times consecutive infusions of 1x109 anti-MESO CAR-T cells each time is planned in the second week. Each subject needs to be observed for at least 2 weeks (14 days) after completing the last infusion. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of anti-MESO CAR-T cells.

Details
Condition Refractory Malignant Solid Neoplasm
Treatment anti-MESO CAR T cells
Clinical Study IdentifierNCT04981691
SponsorRuijin Hospital
Last Modified on22 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Ability to understand and the willingness to provide written informed consent
Advanced pancreatic cancer, ovarian cancer, malignant mesothelioma, gastric cancer, bowel cancer, etc., diagnosed by histopathological or cytological examination, but not limited to subjects with various advanced solid tumors
IHC test showed Mesothelin positive expression at least 1+ in tumor tissue
Age no less than 18 years
Life expectancy greater than 3 months
According to the RECIST (Response Evaluation Criteria in Solid Tumors) standard, there must be measurable lesions
Evidence of metastatic disease and failure of at least 1 prior chemotherapy for metastatic disease. During the last treatment or after the treatment, the disease progressed and was confirmed (the investigator judged according to the RECIST 1.1 standard)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 during the screening period and before apheresis
Adequate liver/bone marrow function
Female subjects must meet the following conditions: infertility or fertility and use high-efficiency contraceptive measures
Male subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 3 months following the last dose of the study cell infusion. Moreover, all men are absolutely prohibited from donating sperm within 1 year after receiving the last study treatment infusion

Exclusion Criteria

Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to entry into the study
Received any anticancer medication in the 2 weeks prior to receiving their first dose of study treatment, including but not limited to surgery, systemic chemotherapy, radiotherapy, intervention, etc
Uncontrolled thyroid dysfunction (serum thyroid hormone determination TT4, TT3, FT3, FT4, and serum thyroid-stimulating hormone TSH) are not suitable for enrolling in the study
Pregnant or breastfeeding female, or not willing to take contraception measures during the study
Any uncontrollable active infection, including but not limited to active tuberculosis; HBV infection (including HBsAg positive, or HBcAb positive and HBV DNA positive); HIV, syphilis, hepatitis C positive or suffering from other fatal viruses, Bacterial disease
Administrated with steroids (5 mg/day or more dexamethasone, or equivalent hormone drugs) within the past two weeks
Other uncontrolled diseases may cause abnormal death of the patient
Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks
Previously allergic to immunotherapy, tocilizumab, cyclophosphamide, fludarabine, and other related drugs, previous history of severe allergies, to research product excipients (such as human serum albumin, DMSO, and dextran 40 ); people who have a history of penicillin allergy and have a positive skin test at the time of screening
Congestive heart failure, uncontrolled cardiac arrhythmia, etc
Uncontrollable massive ascites, that cannot be drained by standard methods
Intestinal obstruction or CT suggesting omental cake-like peritoneal metastasis, or repeated uncontrollable incomplete intestinal obstruction
Have received any genetic engineering modified T cell therapy (including CAR T, TCR T cell)
Uncontrolled brain metastasis or mental illness
Suffered from other uncured malignant tumors within the past 3 years or at the same time
The blood oxygen saturation 95% at the time of screening and before apheresis
Can't be followed up or obey protocol
The investigator believes that it is not appropriate to participate in the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note